Nemolizumab for chronic pruritus beyond atopic dermatitis and prurigo nodularis: a systematic review and synthesis of emerging evidence
Nemolizumab shows plausible antipruritic activity across CP phenotypes, yet the evidence base remains fragile; these signals justify cautious experimental use and prioritize etiology-specific IL-31 receptor blockade trials beyond AD/PN.
Authors
- Aarthy Uthayakumar (ORCID: https://orcid.org/0000-0002-5331-894X)
- Mohammed Shanshal
Institutions
- Imperial College Healthcare NHS Trust (GB)
- NIHR Imperial Biomedical Research Centre (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1080/09546634.2026.2612882
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00